LONDON, July 1 Silence Therapeutics plc (London AIM: SLN)('the Company') today announced changes to its Board of Directors as part ofthe company's plan for growth.
Effective today, Silence has appointed Annette Clancy and Jerry Randall asnon-executive directors and Iain Rugheimer has resigned as a director of theCompany.
Annette Clancy is joining the Board in her first non-executive directorrole. Ms. Clancy (53) is currently with GlaxoSmithKline (GSK), where she hashad a distinguished career spanning 30 years, and will be leaving GSK at theend of the year. She has 15 years experience in Business Development, leadingGSK's global Transactions and Alliance Management teams for the past 3 years,and during her tenure she and her team have been responsible for concluding alarge number of research, development and commercial business collaborationson behalf of GSK. Prior to her role in Business Development, Ms. Clancy held anumber of positions in Clinical Research, R&D project management andCommercialization. Ms. Clancy has a BSc (Hons) Pharmacology from BathUniversity.
Jerry Randall has been Chief Financial Officer of Sinclair Pharmaceuticalsplc since 2000 when he joined as part of a management buy-in team. Prior tothis, Mr. Randall worked in corporate finance with Gambit Corporate Finance.Previously, Mr. Randall had been involved in two other buy-ins and acted asadviser to both private and quoted companies between 1993 and 2000, in boththe capacity as nominated adviser and in practice with KPMG. During thisperiod, Mr. Randall (43) was involved in a number of flotations andtransactions on the Official List, Unlisted Securities Market and theAlternative Investment Market, as well as raising private equity. Mr. Randallqualified as a chartered accountant with KPMG in 1990. Mr. Randall has abeneficial interest in 10,000 ordinary shares of Silence Therapeutics plc.
Iain Rugheimer has been on the Board of Silence Therapeutics plc (formerlySR Pharma plc) since 1995, was briefly Chairman of the Group in 2004, and hasbeen Chairman of the Audit Committee for a number of years.
Commenting on the changes, Iain Ross, Chairman, Board of Directors ofSilence Therapeutics, commented, "I would like to thank Iain Rugheimer for hiscontribution over the years and especially for his personal support and adviceover the last four years as we have sought to transform the Company. He willbe missed and, on behalf of the Board, I wish him every success in the future.I am delighted to take this opportunity to welcome Annette Clancy and JerryRandall to the Board. Both of them bring a wealth of experience and contactsin the industry and with the Company at such an exciting stage of itsdevelopment, I am pleased that we have been able to attract two such talentedindividuals."
There are no other matters to report under schedule 2(g) of the AIM Rulesin respect of either director.
Notes to Editors:
About Silence Therapeutics plc (http://www.silence-therapeutics.com)
Silence Therapeutics plc (AIM: SLN) is a leading European RNAi focusedbiotechnology company. RNAi can selectively 'silence' genes linked to theonset of disease. RNAi is a Nobel Prize winning technology and one of the mostpromising areas of drug discovery and development today.
Silence Therapeutics has developed a platform of novel short interferingRNA ('siRNA') molecules, AtuRNAi, which provide a number of advantages overconventional siRNA molecules, including increased stability against nucleasedegradation. In addition, the Company has developed a proprietary systemicdelivery system, AtuPLEX. This system enables the functional delivery of siRNAmolecules to targeted diseased tissues and cells, while increasing theirbioavailability and intracellular uptake.
Silence's lead internal product, Atu027, is a proprietary AtuRNAi moleculein preclinical developm